| Net income | 40.76M |
| Depreciation | 7.99M |
| Amortization of intangible assets | 9.68M |
| Stock-based compensation expense | 4.8M |
| Deferred compensation expense | |
| Gain on sale of fixed assets and acquisition of business | |
| Stock warrants revaluation | |
| (Increase) decrease in cash surrender value of life insurance | |
| Deferred financing amortization | 453K |
| Amortization of debt discount and bond costs | |
| Interest paid-in-kind | |
| Amortization of loss on interest rate swap agreements | |
| Change in fair value of derivative financial instruments | |
| Trade receivables | -27.21M |
| Inventories | -9.68M |
| Prepaid expenses and other | 1.39M |
| Accounts payable and accrued liabilities | 23.38M |
| Payments on deferred compensation obligations | |
| Net cash used in operating activities | 49.73M |
| Capital expenditures | -10.87M |
| Proceeds from sale of property, equipment and facilities | 241K |
| Business acquisitions | -112.08M |
| Insurance premiums paid | |
| Net cash provided by (used in) investing activities | -122.73M |
| Long-term debt borrowings (payments), net | |
| Short-term debt borrowings (payments), net | |
| Proceeds from life insurance policy loans | |
| Payment on termination of interest rate swap agreements | |
| Payment of deferred financing/debt issuance costs | -380K |
| Proceeds from exercise of stock options, including tax benefit | |
| Proceeds from exercise of warrants to purchase common stock | |
| Other | -62K |
| Net cash provided by (used in) financing activities | 74.38M |
| Increase (decrease) in cash and cash equivalents | 1.39M |
| Cash and cash equivalents at beginning of year | 87K |
| Cash and cash equivalents at end of period | 1.48M |